Pasar al contenido principal

ENFOQUES EVOLUTIVOS PRESERVADORES DE LA EFICACIA DE LOS ANTIBIOTICOS

PID2023-149913OA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Use of adjuvants to improve antibiotic efficacy and reduce the burden of antimicrobial resistance

  • Gil-Gil, Teresa
  • Laborda, Pablo
  • Martínez Menéndez, José Luis
  • Hernando-Amado, Sara
The increase in antibiotic resistance, together with the absence of novel antibiotics, makes mandatory the introduction of novel strategies to optimize the use of existing antibiotics. Among these strategies, the use of molecules that increase their activity looks promising., JL Martínez and S Hernando-Amado are supported by the Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (MCIN/AEI) 10.13039/501100011033, respectively, through grants PID2020-113521RB-I00 and PID2023-149913OA-I00., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa

  • Hernando-Amado, Sara
  • Gomis-Font, María A
  • Valverde, José R.
  • Oliver, Antonio
  • Martínez Menéndez, José Luis
Ceftazidime-avibactam is a β-lactam/β-lactamase inhibitor combination restricted for the treatment of multidrug-resistant infections of Pseudomonas aeruginosa non-susceptible to ceftazidime and resistant to carbapenems. Crucially, it has not been studied if its use could allow the design or application of new or stablished evolution-based strategies that exploit the increased susceptibility that emerges when resistance is acquired (collateral sensitivity, CS). Works in the field have focused on the study of CS in model strains, but to be exploited it must robustly emerge in pre-existing resistant mutants that can coexist in a patient. This is the first analysis of CS robustness on this last-resort drug. We evolved 15 clinical isolates on ceftazidime-avibactam and in absence of inhibitor, and here we show that we found no robust -exploitable- pattern of CS. This, together with the selection of cross-resistance and the impossibility of using previously described CS-based strategies, supports that avibactam should be restricted for the treatment of particular genotypes., This work was supported by MICIU/AEI/10.13039/501100011033 and FEDER (UE) -grant PID2023-149913OA-I00- to S.H.A. and by the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU -grants PI21/00017 and Personalized and precision medicine grant MePRAM Project PMP22/00092- to A.O. The MICIU/AEI/ 10.13039/501100011033 is also acknowledged for supporting the National Center for Biotechnology through the “Severo Ochoa” grant CEX2023-001386-S., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ciprofloxacin resistance rapidly declines in nfxB defective clinical strains of Pseudomonas aeruginosa

  • Hernando-Amado, Sara
  • Laborda, Pablo
  • La Rosa, Ruggero
  • Molin, Søren
  • Johansen, Helle Krogh
  • Martínez Menéndez, José Luis
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-025-60330-2, Antibiotic-resistant bacteria could be tackled by identifying trade-offs of evolution, such as high fitness costs, which may be harnessed to force reversion to susceptibility. A decline in antimicrobial resistance can occur through compensatory mutations or by genetic reversion to the wild-type allele, which reduce fitness costs associated with resistance. We analyse here the impact of antibiotic-free environments on declining ciprofloxacin resistance in eight nfxB defective clinical strains of Pseudomonas aeruginosa spanning varied clone types and ciprofloxacin resistance levels. Ciprofloxacin resistance declines in just 100 generations, which is mainly caused by newly acquired mutations in the genes encoding the overproduced efflux pump MexCD-OprJ and not by the reversion of nfxB mutations of the parental strains. The rapid reversion of ciprofloxacin resistance in P. aeruginosa suggests the potential for reusing this essential antibiotic and underlines the need to implement evolution-based approaches against nfxB defective resistant mutant strains., Work was supported by MICIU/AEI/10.13039/501100011033 and FEDER (UE), grant PID2023-149913OA-I00 to SHA and by a Novo Nordisk Foundation (NNF) Challenge grant NNF19OC0056411 to HKJ. PL is the recipient of an ERS/EU RESPIRE4 Marie Skłodowska-Curie Postdoctoral Research Fel- lowship (Ref. nr: R4202305-01047; this project has received funding from the European Respiratory Society and the European Union’s H2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847462). The Novo Nordisk Foundation is also acknowledged for supporting the NNF Center for Biosustainability (NNF18OC0052776) and the MICIU/AEI/ 10.13039/501100011033 is also acknowledged for supporting the National Center for Biotechnology through the “Severo Ochoa” grant CEX2023-001386-S., Peer reviewed